flosz schreef:
[quote=flosz]
The Fantastic Five in Biotech Europe
19 May 2008
Our top picks for 2008Q2 are:
Crucell (NL)
Genmab (DK)
Intercell (AV)
Morphosys (Ger)
Transgene (F)
Furthermore, per company covered by ESN in European biotech, we have included the news items
we can expect in the next few quarters.
[/quote]
Upcoming corporate calendar Top Picks
Transgene (TNG FP, EUR 14.50)
Date Product Event Impact
June 2008 TG4010 Phase IIb results NSCLC at ASCO Important
2008Q2 TG1042 Interim results Phase II/III Not so important
2008Q4 TG4001 Phase III entry Cevical dysplasia Very important
2008Q4 TG4010 Final results Phase IIb NSCLC Very important
2008Q4 TG1042 Start Phase III Cutaneous B-cell Lymphoma Not so important
2008Q4 TG4040 2nd results Phase I/II Hep. C Not so important
2008H2 TG4010 Partnership negotiations Very important
TG1042<>Per.c6 inside!
Morphosys (MOR GR, EUR 42.40)
Date Product Event Impact
Summer 2008 RT1450 Results Phase I Alzheimer disease (partnered with Roche) Very important
Crucell (CRXL, EUR 11.80)
Date Product Event Impact
2008Q2/Q3 Quinvaxem Additional contracts PAHO/Unicef Important
2008Q2 HIV Vaccine Initiate Phase I, in cooperation with Harvard University Less important
2008H2 TB Vaccine Results Phase I Important
2008H2 Malaria Vaccine Conclusion and results Phase I Important
2008H2 TB Vaccine Start Phase II Less Important
Voor Genmab, zie biopharma-forum.